<DOC>
	<DOCNO>NCT00083174</DOCNO>
	<brief_summary>RATIONALE : The MAP.3 study design test whether hormone therapy use exemestane may prevent breast cancer block production estrogen . This study analyze April 2011 show 65 % reduction incidence invasive breast cancer woman receive exemestane compare woman placebo . PURPOSE : The study protocol amend May 2011 current purpose study allow study participant opportunity complete 5 year exemestane .</brief_summary>
	<brief_title>Exemestane Preventing Cancer Postmenopausal Women Increased Risk Developing Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary Previously : To determine exemestane reduces incidence invasive breast cancer compare placebo . Currently : To determine frequency serious adverse event post-menopausal woman high-risk develop breast cancer choose receive 5 year exemestane preventative therapy . Secondary Previously : ( currently list PDQ ) Currently : To address Trial Committee Sponsor 's commitment allow woman randomize MAP.3 trial receive 5 year exemestane therapy . OUTLINE : This study randomize , double-blind , placebo-controlled , multicentre study . Protocol-specified analysis perform April 2011 . The result analysis post Results section . Following amendment May 2011 , study open-label eligible patient receive exemestane participate site total 5 year . After exemestane stop , follow-up . PROJECTED ACCRUAL : There 4560 woman United States , Canada , Spain France take part study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>At increase risk develop breast cancer , due least one follow risk factor : Gail score ≥ 1.66 Age ≥ 60 year Prior atypical ductal hyperplasia , lobular hyperplasia , lobular carcinoma situ breast biopsy Prior ductal carcinoma situ ( DCIS ) treat total mastectomy without tamoxifen ( tamoxifen must complete ≥ 3 month prior randomization ) No prior DCIS treat lumpectomy without radiation No prior invasive breast cancer Not BRCA1 BRCA2 carrier PATIENT CHARACTERISTICS : Previous : 35 Female Postmenopausal , define one following : 50 year age spontaneous menses least 12 month study entry 50 year age menses ( spontaneous secondary hysterectomy ) least 12 month study entry AND folliclestimulating hormone level within postmenopausal range Underwent prior bilateral oophorectomy No malignancy within past 5 year except adequately treat nonmelanoma skin cancer , curatively treat carcinoma situ cervix , curatively treat solid tumor evidence disease ≥ 5 year No uncontrolled hypothyroidism hyperthyroidism No major medical psychiatric illness ( include substance alcohol abuse within past 2 year ) would preclude study participation compliance Must accessible treatment followup Willing complete quality life questionnaires either English French Current : MAP.3 participant randomize exemestane arm , currently receive exemestane part MAP.3 study complete 5 year exemestane . OR MAP.3 study participant randomize placebo arm either complete 5 year study drug still receive placebo . Note : applies centre choose allow placebo `` crossover '' . PRIOR CONCURRENT THERAPY : Previous : More 3 month since prior concurrent hormone replacement therapy More 3 month since systemic estrogenic , androgenic , progestational agent More 3 month since prior concurrent hormonal therapy , include , limited following : Luteinizinghormone releasinghormone analog ( e.g. , goserelin leuprolide ) Progestogens ( e.g. , megestrol ) Prolactin inhibitor ( e.g. , bromocriptine ) Antiandrogens ( e.g. , cyproterone acetate ) Selective estrogenreceptor modulators ( e.g. , tamoxifen , toremifene , raloxifene ) No investigational drug within 30 day 5 half life prior randomization No concurrent endocrine therapy No concurrent estrogen , androgen , progesterone Concurrent low dose ( ≤ 100 mg/day ) prophylactic aspirin allow Concurrent bisphosphonates prevention treatment osteoporosis allow No concurrent medication may effect study endpoint Current : There prior concurrent therapy restriction amend MAP.3 study .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>